title: [Effect of polymorphism of human intestinal fatty acid binding protein gene on the therapeutic efficacy of fenofibrate].
abstract: OBJECTIVE
  To explore the effect of polymorphism in codon Ala54Thr of human intestinal fatty acid-binding protein gene (IFABP) on the therapeutic efficacy of fenofibrate.
  
  
  METHODS
  Totally 147 patients with hyperlipidemia [72 men mean age: (56.2 +/- 8.63) years; 75 women mean age: (58.4 +/- 9.12) years] were enrolled. IFABP genotypes were detected by polymerase chain reaction, Hha I digestion, and sequencing. Four weeks before and after treatment, the levels of fasting serum total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein A I (apoA I) and apolipoprotein B (apoB) were detected with biochemical techniques.
  
  
  RESULTS
  The frequency of IFABP genotype was 0.47 for A/A, 0.37 for A/T, and 0.16 for T/T, and the allelic frequency was 0.65 for A and 0.35 for T. No significant different was found in lipid levels in every genotype before treatment (P > 0.05). After 4 weeks of treatment, the levels of TC, TG, LDL-C, and apoB significantly decreased (P < 00.01), and the levels of HDH-C and apoA I significantly increased (P < 0.01). The total therapeutic efficacy on A54A and A54T were 97% and 95%, respectively. In the patients with T54T genotype after treatment, no significant difference in lipids levels was found except TG (P < 0.05), and the total efficacy was only 38%. The total therapeutic efficacies of fenofibrate on A54A and A54T were higher than those of T54T, and there was significant different between A54A and T54T (P < 0.01).
  
  
  CONCLUSIONS
  The polymorphism of human IFABP gene in hyperlipidemia is related with the therapeutic efficacy of fenofibrate, and the T54T IFABP genotype may have strong negative effect on such efficacy.
authors.affiliation: Department of Biochemistry, Hebei North University, Zhangjiakou 075029, China. changxt1212@vip.sina.com
authors.forename: Xiao-tong
authors.initials: XT
authors.lastname: Chang
authors.forename: Zhen-hui
authors.initials: ZH
authors.lastname: Wang
authors.forename: Xin
authors.initials: X
authors.lastname: Du
authors.forename: Ming-gang
authors.initials: MG
authors.lastname: Dong
authors.forename: Li-juan
authors.initials: LJ
authors.lastname: Hou
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.forename: Jian-guang
authors.initials: JG
authors.lastname: Zhou
mesh_terms: D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D050556:Fatty Acid-Binding Proteins / Q000235:genetics*; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D016896:Treatment Outcome
chemical_list: D001053:Apolipoproteins; D050556:Fatty Acid-Binding Proteins; D000960:Hypolipidemic Agents; D008055:Lipids; D011345:Fenofibrate